Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (5448)	10/4/1998 11:57:00 AM
From: John Metcalf	Read Replies (3) of 6136

DuPont expects to net in excess of $3B from selling a fraction of Conoco to the public, then spinning off the balance of the unit to shareholders next year. This revised plan was announced last Monday, and Conoco received its own debt rating of Friday. The rise in Agouron's share price is immaterial to DD's acquisition plans (if there are any). AGPH's shareholder rights plan limits any share acquisition in the market to less than 15% of total shares, or provisions dilutive to the acquirer would be exercised. Agouron has independence now as a profitable company, and would not be sold at less than a significant premium to market, IMHO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next